
June 25 (Reuters) - Corbus Pharmaceuticals Holdings Inc CRBP.O:
CORBUS PHARMACEUTICALS ANNOUNCES FIRST PATIENT DOSED WITH ITS NECTIN-4 TARGETING ADC CRB-701 IN COMBINATION WITH PEMBROLIZUMAB
CORBUS PHARMACEUTICALS HOLDINGS: EXPECTS TO PROVIDE DATA UPDATE & ESTABLISH RECOMMENDED PHASE 2 DOSE IN Q4 THIS YEAR